A New Drug BY002 for Relapsed Acute Leukemia with Genetic Changes
Part of Blood & lymphatic, Cancer clinical trials.
This phase 1 trial tests a new drug called BY002 for people with certain types of leukemia (AML, ALL, or MPAL) that have come back or not responded to treatment. It focuses on patients whose leukemia has a specific genetic change (KMT2A rearrangement or NPM1 mutation). The goal is to see if BY002 can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 16 years or older.
- You have a confirmed diagnosis of acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or mixed phenotype acute leukemia (MPAL).
- Your leukemia has come back after treatment or did not respond to at least one prior therapy.
- Your leukemia has a change in the KMT2A gene or NPM1 gene (this is preferred but not required).
- You are able to do daily activities with minimal help (ECOG performance status 0, 1, or 2).
- Your major organs (kidneys, liver, heart) are working well enough, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug for people with acute myeloid leukemia (AML) that has come back or hasn't responded to standard therapies, and whose leukemia has certain genetic markers. The drug may target these specific changes to help stop the cancer.
This trial tests a new drug, BT02, for people with blood cancers like leukemia, lymphoma, or multiple myeloma that have returned or not improved after treatment. The goal is to see if BT02 can help control the cancer.
This study tests an experimental drug called TCB008 given through an IV. It is for people with acute myeloid leukemia (AML) or a related condition called MDS/AML that has come back or not gone away after prior treatment. The goal is to see if the drug is safe and if it helps.
This trial tests an oral investigational drug (GLB-001) for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that has returned or hasn't responded to other treatments. The goal is to see if it's safe and effective for those who have run out of standard options.
This study tests a new drug called BG-75202, alone or combined with other treatments, for myeloid malignancies (blood cancers affecting bone marrow cells) that have returned or stopped responding to previous treatment. The goal is to see if this drug can help control the cancer.
This trial tests a new drug, GLB-002, for people with non-Hodgkin lymphoma that has come back or hasn't responded to other treatments. The goal is to see if GLB-002 is safe and whether it can help shrink or control the lymphoma.
Hear when a new Acute Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.